Driven by the cost advantage and a better availability of talent pool, the 
total Indian pharmaceutical outsourcing industry in the country is expected to 
cross 2.5 billion-dollar mark by 2012. 

"Indian pharmaceutical offshoring industry is set to become a 2.5 billion 
opportunity by 2012,"a study titled 'Indian Pharmaceutical offshoring industry' 
done by the management consulting firm Zinnov said. 

One of the key factors driving the offshoring wave is increasing research and 
development(R&D) costs incurred in both development and manufacturing of new 
drugs, which in-turn is compelling global pharmaceutical organisations in the 
US and EU to look for new low cost R&D destinations such as India and China, it 
added. 

Basic production cost of medicines in India is up to 50 per cent lower than in 
the US. A US Food and Drug Authority (FDA) approved plant can be constructed in 
India at 30-50 per cent lower costs, compared with established markets, the 
study pointed out. 

Out of the projected 2.5 billion-dollar market by 2012, contract manufacturing 
accounts for the maximum share as the total manufacturing outsourcing business 
in India will cross 900 million dollars by 2010 followed by clinical trials 
which are growing at the compound annual growth rate of 31 per cent and are set 
to become 608 million-dollar industry by 2012. 

India's rich talent pool, nearly 13.5 million science graduates growing at the 
rate of 36 per cent, plays a major role in the growth of outsourcing 
development process, the study said

http://www.financialexpress.com/news/pharma-outsourcing-biz-to-cross-2.5-bn/366310/

Trouble shared is trouble halved. 
>>>>>>>>>>>>>>>Lee Iacocca






--~--~---------~--~----~------------~-------~--~----~
You received this message because you are subscribed to the Google Groups 
"Kences1" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to [EMAIL PROTECTED]
For more options, visit this group at 
http://groups.google.com/group/kences1?hl=en
-~----------~----~----~----~------~----~------~--~---

Reply via email to